Company intelligence / Profile preview

Kontigo Care

Ownership: Private
Employees: ~12
Development stage: Commercial

Overview

Kontigo Care’s digital platform Previct has been commercialized and deployed in the Nordic market for real-time sobriety testing and behavioral analysis to support early relapse detection and therapy enhancement. The company has published scientific articles supporting its approach[1][2][3].

Therapeutic areas: Psychiatry
Modalities: DeviceDigital therapeutic platform
Industry: Digital Health Medical Devices

Drug pipeline

2 assets

Previct Alcohol

Commercial

Indications: Alcohol dependence

1 more asset in the full pipeline.

Request access →

Partnerships

No major pharmaceutical or biotech partnerships publicly disclosed as of June 2025.

Beyond the preview

Go deeper on Kontigo Care.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Kontigo Care.

Explore the full profile